NEOS Investment Management LLC Boosts Stock Holdings in Guardant Health, Inc. (NASDAQ:GH)

NEOS Investment Management LLC grew its position in Guardant Health, Inc. (NASDAQ:GH) by 10.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,120 shares of the company’s stock after purchasing an additional 3,553 shares during the period. NEOS Investment Management LLC’s holdings in Guardant Health were worth $1,103,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. R Squared Ltd bought a new position in Guardant Health in the 4th quarter valued at $26,000. SBI Securities Co. Ltd. bought a new position in Guardant Health during the fourth quarter valued at about $43,000. Kimelman & Baird LLC bought a new position in Guardant Health during the fourth quarter valued at about $58,000. Quantbot Technologies LP purchased a new stake in Guardant Health during the fourth quarter worth about $80,000. Finally, Jones Financial Companies Lllp raised its position in Guardant Health by 43.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock worth $82,000 after acquiring an additional 817 shares during the period. 92.60% of the stock is owned by institutional investors.

Guardant Health Stock Down 4.5 %

Shares of NASDAQ GH opened at $43.14 on Friday. The firm has a market capitalization of $5.32 billion, a P/E ratio of -12.12 and a beta of 1.50. The stock’s 50-day simple moving average is $44.66 and its two-hundred day simple moving average is $34.30. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $50.89.

Guardant Health (NASDAQ:GH) last announced its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $201.81 million during the quarter, compared to analysts’ expectations of $192.50 million. As a group, research analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Raymond James restated an “outperform” rating and set a $59.00 price target (up previously from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Scotiabank boosted their target price on Guardant Health from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Monday, February 24th. Stifel Nicolaus upped their price target on Guardant Health from $45.00 to $53.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Guggenheim reissued a “buy” rating and issued a $56.00 price objective on shares of Guardant Health in a report on Monday, February 24th. Finally, Stephens reaffirmed an “overweight” rating and set a $55.00 price objective on shares of Guardant Health in a report on Wednesday. Twenty analysts have rated the stock with a buy rating, According to data from MarketBeat, Guardant Health currently has an average rating of “Buy” and an average price target of $48.95.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.